These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
101 related articles for article (PubMed ID: 15477125)
1. Effects of inhaled formoterol compared with salbutamol in ventilated preterm infants. Rieger-Fackeldey E; Reinhardt D; Schulze A Pulm Pharmacol Ther; 2004; 17(5):293-300. PubMed ID: 15477125 [TBL] [Abstract][Full Text] [Related]
2. Assessment of a relative therapeutic index between inhaled formoterol and salbuterol in asthma patients. Rosenborg J; Larsson P; Rott Z; Böcskei C; Poczi M; Juhász G Eur J Clin Pharmacol; 2002 Jul; 58(4):S61-7. PubMed ID: 12214580 [TBL] [Abstract][Full Text] [Related]
3. The pulmonary and extra-pulmonary effects of high-dose formoterol in COPD: a comparison with salbutamol. Goldkorn A; Diotto P; Burgess C; Weatherall M; Holt S; Beasley R; Siebers R Respirology; 2004 Mar; 9(1):102-8. PubMed ID: 14982610 [TBL] [Abstract][Full Text] [Related]
4. Beclometasone-formoterol as maintenance and reliever treatment in patients with asthma: a double-blind, randomised controlled trial. Papi A; Corradi M; Pigeon-Francisco C; Baronio R; Siergiejko Z; Petruzzelli S; Fabbri LM; Rabe KF Lancet Respir Med; 2013 Mar; 1(1):23-31. PubMed ID: 24321801 [TBL] [Abstract][Full Text] [Related]
5. The duration of action of inhaled formoterol dry powder. Quebe-Fehling E; Brambilla R; Bromly CL; Fishwick K; Walters EH; Hendrick DJ Br J Clin Pract; 1996 Dec; 50(8):446-9. PubMed ID: 9039716 [TBL] [Abstract][Full Text] [Related]
6. Safety and tolerability of high-dose formoterol (via Aerolizer) and salbutamol in patients with chronic obstructive pulmonary disease. Rosenkranz B; Rouzier R; Kruse M; Dobson C; Ayre G; Horowitz A; Fitoussi S Respir Med; 2006 Apr; 100(4):666-72. PubMed ID: 16303295 [TBL] [Abstract][Full Text] [Related]
7. Beta2-adrenoceptor regulation and bronchodilator sensitivity after regular treatment with formoterol in subjects with stable asthma. Aziz I; Hall IP; McFarlane LC; Lipworth BJ J Allergy Clin Immunol; 1998 Mar; 101(3):337-41. PubMed ID: 9525449 [TBL] [Abstract][Full Text] [Related]
8. Long duration of airway but not systemic effects of inhaled formoterol in asthmatic patients. Lötvall J; Ankerst J Respir Med; 2008 Mar; 102(3):449-56. PubMed ID: 18023335 [TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of budesonide/formoterol compared with salbutamol in the treatment of acute asthma. Balanag VM; Yunus F; Yang PC; Jorup C Pulm Pharmacol Ther; 2006; 19(2):139-47. PubMed ID: 16009588 [TBL] [Abstract][Full Text] [Related]
10. Cross tolerance to salbutamol occurs independently of beta2 adrenoceptor genotype-16 in asthmatic patients receiving regular formoterol or salmeterol. Lee DK; Jackson CM; Bates CE; Lipworth BJ Thorax; 2004 Aug; 59(8):662-7. PubMed ID: 15282385 [TBL] [Abstract][Full Text] [Related]
11. Safety and tolerability of high-dose formoterol (Aerolizer) and salbutamol (pMDI) in patients with mild/moderate, persistent asthma. Kruse M; Rosenkranz B; Dobson C; Ayre G; Horowitz A Pulm Pharmacol Ther; 2005; 18(3):229-34. PubMed ID: 15707858 [TBL] [Abstract][Full Text] [Related]
12. Total reversibility testing as indicator of the clinical efficacy of formoterol in COPD. Molimard M; Bourcereau J; Le Gros V; Bourdeix I Respir Med; 2005 Jun; 99(6):695-702. PubMed ID: 15878485 [TBL] [Abstract][Full Text] [Related]
13. Doppler echocardiographic assessment of the effects of inhaled long-acting beta2-agonists on pulmonary artery pressure in COPD patients. Cazzola M; Mantero A; Santus P; Carlucci P; Mondoni M; Bosotti L; Centanni S Pulm Pharmacol Ther; 2007; 20(3):258-64. PubMed ID: 16600647 [TBL] [Abstract][Full Text] [Related]
14. Inhaled formoterol during one year in asthma: a comparison with salbutamol. Arvidsson P; Larsson S; Löfdahl CG; Melander B; Svedmyr N; Wåhlander L Eur Respir J; 1991 Nov; 4(10):1168-73. PubMed ID: 1687129 [TBL] [Abstract][Full Text] [Related]
15. Comparison of the bronchodilating effects of inhaled formoterol, salmeterol and salbutamol in asthmatic patients. Grembiale RD; Pelaia G; Naty S; Vatrella A; Tranfa CM; Marsico SA Pulm Pharmacol Ther; 2002; 15(5):463-6. PubMed ID: 12406669 [TBL] [Abstract][Full Text] [Related]
16. Influence of respiratory efforts on b2-agonist induced bronchodilation in mechanically ventilated COPD patients: a prospective clinical study. Malliotakis P; Mouloudi E; Prinianakis G; Kondili E; Georgopoulos D Respir Med; 2007 Feb; 101(2):300-7. PubMed ID: 16774821 [TBL] [Abstract][Full Text] [Related]
17. Profiles of measured and perceived bronchodilation. A placebo-controlled cross-over trial comparing formoterol and salmeterol in moderate persistent asthma. Schermer TR; Hoff WJ; Greefhorst AP; Creemers JP; Sips AP; Westbroek J; van Herwaarden CL Pulm Pharmacol Ther; 2004; 17(4):205-12. PubMed ID: 15219265 [TBL] [Abstract][Full Text] [Related]
18. Efficacy, tolerability, and effect on asthma-related quality of life of formoterol bid via multidose dry powder inhaler and albuterol QID via metered dose inhaler in patients with persistent asthma: a multicenter, randomized, double-blind, double-dummy, placebo-controlled, parallel-group study. Busse W; Levine B; Andriano K; Lavecchia C; Yegen U Clin Ther; 2004 Oct; 26(10):1587-98. PubMed ID: 15598475 [TBL] [Abstract][Full Text] [Related]
19. Safety of formoterol after cumulative dosing via Easyhaler and Aerolizer. Randell J; Saarinen A; Walamies M; Vahteristo M; Silvasti M; Lähelmä S Respir Med; 2005 Dec; 99(12):1485-93. PubMed ID: 16226024 [TBL] [Abstract][Full Text] [Related]
20. Treatment of persistent asthma with Symbicort (budesonide/formoterol inhalation aerosol): an inhaled corticosteroid and long-acting beta2-adrenergic agonist in one pressurized metered-dose inhaler. Berger WE; Noonan MJ J Asthma; 2010 May; 47(4):447-59. PubMed ID: 20528601 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]